| Name | Title | Contact Details |
|---|
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Auspex Pharmaceuticals, Inc. develops deuterated analogs of clinically-validated drugs. Its technology replaces metabolically-sensitive hydrogen atoms with its non-radioactive isotope deuterium to create therapeutics. The company was founded in 2001 and is based in La Jolla, California.
Patient Focus Systems is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Active Healthcare is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Definity Health is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.